Convalife has submitted its listing application to the Hong Kong Stock Exchange (HKEX) with a post-C2 round valuation of RMB 3.19 billion (USD 447 milion). The Shanghai-based oncology-focused biotech commercialised its first product pan-HER inhibitor neratinib in June 2024 and maintains four core candidates, including neratinib, PARP inhibitor mefuparib, PD-L1/VEGF bispecific CVL006 and PI3Kβ/δ inhibitor conpelisib. The company has raised RMB 416 million (USD 58 million) across four funding rounds since its 2015 founding.

Convalife employs a «one drug, multiple indications» strategy across its pipeline, with lead asset mefuparib holding an orphan drug designation (ODD) for cholangiocarcinoma and pancreatic cancer in the US. The company reported RMB 34.7 million revenue in H1 2025 alongside RMB 35.9 million net loss. Proceeds will fund clinical trials, AI drug discovery platform development and international expansion through partnerships with Henlius and Sinovac.

PharmCube's NextBiopharm® database shows that conpelisib became the first-in-class PI3Kβ/δ inhibitor globally after Gilead and AstraZeneca terminated their respective programs. Click here to request a free trial for NextBiopharm®.